| Nov 12 |
BridgeBio Pharma: Q3 Earnings Snapshot
|
| Nov 12 |
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
|
| Nov 5 |
BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management
|
| Oct 31 |
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
|
| Oct 24 |
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
|
| Oct 23 |
Investors in BridgeBio Pharma (NASDAQ:BBIO) have unfortunately lost 49% over the last three years
|
| Oct 4 |
3 Top Stocks That Could Still Rocket Higher in 2024
|
| Oct 3 |
BridgeBio granted Perform rating at Oppenheimer on market challenges
|
| Oct 3 |
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
|
| Oct 1 |
5 FDA decisions to watch in the fourth quarter
|
